Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2021 16:16 ET | Source: Otonomy, Inc.

Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update

OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022OTO-413 Phase 1/2 trial expansion in hearing loss ongoing with results expected in mid-2022OTO-825 preclinical...
July 28, 2021 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report Second Quarter 2021 Financial Results and Provide Corporate Update

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
June 15, 2021 07:30 ET | Source: Otonomy, Inc.

Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss

OTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing tests in dose escalation efficacy cohortExpansion study will support endpoint selection...
May 14, 2021 07:30 ET | Source: Otonomy, Inc.

Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting

SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
May 11, 2021 16:17 ET | Source: Otonomy, Inc.

Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update

OTO-313 Phase 2 trial in tinnitus initiated with results expected in mid-2022OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in...
May 04, 2021 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update

SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will...
April 28, 2021 07:30 ET | Source: Otonomy, Inc.

Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting

SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
April 19, 2021 07:30 ET | Source: Otonomy, Inc.

Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
April 07, 2021 22:02 ET | Source: Otonomy, Inc.

Otonomy Announces Pricing of $30.1 Million Public Offering

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
April 07, 2021 16:06 ET | Source: Otonomy, Inc.

Otonomy Announces Proposed Public Offering

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right